Related Experiment Videos
Specific imaging of dialysis-related amyloid deposits using 131I-beta-2-microglobulin
J Floege1, B Nonnast-Daniel, P Gielow
1Department of Nephrology, Medizinische Hochschule Hannover, FRG.
Abstract:
Dialysis-related amyloidosis (DRA), characterized by its association with beta 2-microglobulin (beta 2m), has become a major concern in long-term hemodialysis patients. Hitherto the diagnosis was based on histological examinations of tissue obtained by biopsy or during surgery. In this preliminary study a new noninvasive diagnostic method was developed using the affinity of beta 2m for its derived fibrils. 3 patients on long-term hemodialysis for 10-16 years with biopsy-proven DRA and 1 patient on chronic hemodialysis for only 6 months were examined after intravenous injection of 131I-labelled beta 2m. Specific local accumulation of radioactivity was noted in the DRA patients after 48 h, persisting for further 96 h and corresponding to clinically or radiologically evident sites of amyloid deposition and to several other hitherto unsuspected sites. Examination of an excised amyloid tumor subsequent to in vivo labelling confirmed a highly specific accumulation of radioactivity in the amyloid tissue but not in control tissue. In the patient on chronic hemodialysis for only 6 months, no specific local accumulation was detected even after 1 week. These findings provide in vivo evidence in man that a specific uptake of circulating amyloid precursor molecules into deposits occurs and that this uptake may be used to radiolabel even small tissue infiltrates of amyloid. This method therefore may not only allow an objective, noninvasive detection of DRA but may also be used to obtain new pathophysiologic insights into amyloid formation in man, as well as permitting the evaluation of preventive therapeutic strategies in prospective studies on new patients.
Insights
A new imaging technique uses radioactive beta 2-microglobulin (beta 2m) to detect dialysis-related amyloidosis (DRA) noninvasively. This method shows specific uptake in patients with long-term hemodialysis, aiding diagnosis and understanding amyloidosis.
Area of Science:
- Nephrology
- Nuclear Medicine
- Biochemistry
Background:
- Dialysis-related amyloidosis (DRA) is a complication in long-term hemodialysis patients, linked to beta 2-microglobulin (beta 2m).
- Current diagnostic methods for DRA rely on invasive tissue biopsies or surgical examinations.
- There is a need for noninvasive diagnostic tools to detect and monitor DRA.
Purpose of the Study:
- To develop and evaluate a novel, noninvasive diagnostic method for dialysis-related amyloidosis.
- To utilize the affinity of beta 2-microglobulin for its derived fibrils for diagnostic purposes.
- To assess the potential of in vivo radiolabeling for detecting amyloid deposits.
Main Methods:
- Development of a noninvasive diagnostic method using 131I-labelled beta 2m.
- Intravenous injection of 131I-labelled beta 2m in patients with biopsy-proven DRA and a control patient.
- Monitoring of specific local accumulation of radioactivity over time.
- Confirmation of radioactivity accumulation in excised amyloid tissue.
Main Results:
- Specific local accumulation of radioactivity was observed in patients with long-term hemodialysis and DRA.
- Radioactivity accumulation corresponded to known amyloid deposition sites and identified new ones.
- The control patient on short-term hemodialysis showed no specific accumulation.
- Excised amyloid tissue confirmed highly specific radioactivity uptake.
Conclusions:
- The developed method allows for objective, noninvasive detection of dialysis-related amyloidosis.
- This technique provides in vivo evidence of circulating amyloid precursor uptake into deposits.
- The method can potentially offer new pathophysiological insights into amyloid formation and aid in evaluating therapeutic strategies.